Baird Financial Group
ADMA icon

Baird Financial Group’s ADMA Biologics ADMA Stock Holding History

Baird Financial Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-87,317
Closed -$1.59M – 1827
2025
Q4 		$1.59M Sell
87,317
-12,930
-13% -$218K ﹤0.01% 1110
2025
Q3 		$1.47M Sell
100,247
-14,518
-13% -$249K ﹤0.01% 1144
2025
Q2 		$2.09M Buy
+114,765
New +$2.34M ﹤0.01% 1005

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Baird Financial Group's ADMA Position: Q1 2026 in Review

Baird Financial Group sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 87,317 shares — an estimated $1.59M sold.

Baird Financial Group first reported a position in ADMA in Q2 2025 and held it in 3 quarters. The position peaked at $2.09M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Baird Financial Group reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Baird Financial Group sold 87,317 ADMA Biologics shares in Q1 2026, an estimated $1.59M.
  • Baird Financial Group first reported a position in ADMA Biologics in Q2 2025 and held it in 3 quarters.
  • Baird Financial Group's ADMA Biologics position peaked at $2.09M in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.